Enhancing adoptive immunotherapy of cancer

被引:17
作者
Westwood, Jennifer A. [1 ]
Berry, Linda J. [1 ]
Wang, Leanne X. J. [1 ]
Duong, Connie P. M. [1 ]
Pegram, Hollie J. [1 ]
Darcy, Phillip K. [1 ]
Kershaw, Michael H. [1 ]
机构
[1] Peter MacCallum Canc Ctr, Canc Immunol Res Program, Melbourne, Vic 3002, Australia
基金
英国医学研究理事会;
关键词
Bortezomib; cell therapy; chemoimmunotherapy; cost of cell transfer; cyclophosphamide; Gemcitabine; gene therapy; immunotherapy; toll-like receptor; tumor microenvironment; CD8(+) T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; ACTIVATED KILLER-CELLS; IN-VITRO GROWTH; ANTIGEN-SPECIFIC CD8(+); CYTOTOXIC HUMAN-LYMPHOCYTES; TRANSFERRED IMMUNE CELLS; GAMMA-CHAIN CYTOKINES; ANTITUMOR-ACTIVITY; PHASE-I;
D O I
10.1517/14712591003610622
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Importance of the field: Conventional therapies, including surgery, chemotherapy and radiotherapy have contributed much to cancer treatment. However, these treatment modalities fail in a large proportion of patients, and there is a great need for effective alternate therapies. Adoptive immunotherapy can be effective against some cancers that have failed all other treatment options, even when disease burdens are massive. Areas covered in this review: This review gives a brief introduction of the historical origins of adoptive immunotherapy and then provides details of strategies for increasing the potency of cell transfer. Approaches for enhancing adoptive immunotherapy include: selecting the right type of cell; providing cytokine support; preconditioning patients and tuning the tumor microenvironment. The review also provides insights into the safety, feasibility and costs of this form of therapy. What the reader will gain: This article will give the reader an appreciation of the potential of adoptive immunotherapy, as well as an understanding of some limitations and current approaches for optimizing the effectiveness of this approach. Take home message: With recent developments in knowledge of the interactions between the immune system and tumors, the field of adoptive immunotherapy is now poised to make dramatic contributions to cancer therapy.
引用
收藏
页码:531 / 545
页数:15
相关论文
共 181 条
[1]   Interleukin-7 induced facilitation of immunological reconstitution of sublethally irradiated mice following treatment with alloreactive spleen cells in a murine model of B-cell leukemia/lymphoma (BCL1) [J].
Abdul-Hai, A. ;
Weiss, L. ;
Ben-Yehuda, A. ;
Ergas, D. ;
Shapira, M. Y. ;
Slavin, S. .
BONE MARROW TRANSPLANTATION, 2007, 40 (09) :881-889
[2]   Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components [J].
Alici, Evren ;
Sutlu, Tolga ;
Boejrkstrand, Bo ;
Gilljam, Mari ;
Stellan, Birgitta ;
Nahi, Hareth ;
Quezada, Hernan Concha ;
Gahrton, Goesta ;
Ljunggren, Hans-Gustaf ;
Dilber, M. Sirac .
BLOOD, 2008, 111 (06) :3155-3162
[3]  
ANDREWS GA, 1967, CANCER RES, V27, P2535
[4]   CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells [J].
Antony, PA ;
Piccirillo, CA ;
Akpinarli, A ;
Finkelstein, SE ;
Speiss, PJ ;
Surman, DR ;
Palmer, DC ;
Chan, CC ;
Klebanoff, CA ;
Overwijk, WW ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :2591-2601
[5]  
BELLDEGRUN A, 1993, J UROLOGY, V150, P1384, DOI 10.1016/S0022-5347(17)35785-3
[6]   Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma [J].
Bennouna, Jaafar ;
Bompas, Emmanuelle ;
Neidhardt, Eve Marie ;
Rolland, Frederic ;
Philip, Irene ;
Galea, Celine ;
Salot, Samuel ;
Saiagh, Soraya ;
Audrain, Marie ;
Rimbert, Marie ;
Micheaux, Sylvie Lafaye-de ;
Tiollier, Jerome ;
Negrier, Sylvie .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (11) :1599-1609
[7]   Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model [J].
Berger, C ;
Blau, CA ;
Huang, ML ;
Iuliucci, JD ;
Dalgarno, DC ;
Gaschet, J ;
Heimfeld, S ;
Clackson, T ;
Riddell, SR .
BLOOD, 2004, 103 (04) :1261-1269
[8]   Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization [J].
Berger, M ;
Bergers, G ;
Arnold, B ;
Hämmerling, GJ ;
Ganss, R .
BLOOD, 2005, 105 (03) :1094-1101
[9]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[10]   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].
Bonini, C ;
Ferrari, G ;
Verzeletti, S ;
Servida, P ;
Zappone, E ;
Ruggieri, L ;
Ponzoni, M ;
Rossini, S ;
Mavilio, F ;
Traversari, C ;
Bordignon, C .
SCIENCE, 1997, 276 (5319) :1719-1724